secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2025-11-24T23:59:59+00:00
Accession:  0001087294-25-000023
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland amends credit line: reduces revolver to $15M, extends maturity to Oct 2027
--------------------------------------------------------------------------------

- Principal available reduced to $15M (from $20M); right to request additional $10M (up from $5M).
- Maturity extended to October 1, 2027; interest rate is Benchmark Term SOFR + 2.75%.
- New financial covenant: Minimum Fixed Charge Coverage Ratio of 1.75x, replacing Maximum Funded Debt Ratio.
- Borrowing Base Requirements made permanent; company paid $15,000 amendment fee.
- Collateral remains substantially all assets; credit line with Pinnacle Bank.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000108729425000023/0001087294-25-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000108729425000023/cpix-20251118.htm
  HTML page:      https://secwatch.observer/filing/0001087294-25-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer